8-K
filed February 29, 2024, 6:59 PM ET
ticker SENS
CIK 0001616543
earnings
confidence high
sentiment neutral
materiality 0.70
Senseonics Q4 revenue $8.0M (+44% YoY); net loss $17.2M; 365-day FDA submission planned
Senseonics Holdings, Inc.
2023-FY EPS reported
-$0.11
revenue$22,390,000
- Q4 2023 revenue $8.0M vs $5.6M Q4 2022; full-year revenue $22.4M (+37% YoY).
- Net loss $17.2M ($0.03/sh) in Q4 2023 vs net income $11.6M in Q4 2022; loss driven by derivative accounting.
- Medicare expanded Eversense E3 coverage via three MACs; UnitedHealthcare coverage secured.
- ENHANCE pivotal trial completed; 365-day system FDA submission expected in coming weeks; potential Q4 2024 launch.
- First half 2024 revenue outlook ~$10M (+16% YoY); full-year guide deferred to Q2 2024.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Senseonics Holdings, Inc. reported the quarter and year ended December 31, 2023 results: revenue $22.4 million, net income Net loss was $60.4 million, EPS $0.11 per share.
- Period
- the quarter and year ended December 31, 2023
- Revenue
- $22.4 million
- Net income
- Net loss was $60.4 million
- EPS
- $0.11 per share
- Result
- reported results
Exact text from the filing
Total revenue for the fourth quarter of 2023 was $8.0 million compared to $5.6 million for the fourth quarter of 2022.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Senseonics Holdings, Inc. reported the quarter and year ended December 31, 2023 results: revenue $22.4 million, net income Net loss was $60.4 million, EPS $0.11 per share.
- Period
- the quarter and year ended December 31, 2023
- Revenue
- $22.4 million
- Net income
- Net loss was $60.4 million
- EPS
- $0.11 per share
- Result
- reported results
Exact text from the filing
Total revenue for 2023 was $22.4 million compared to $16.4 million in 2022.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.